Navigation Links
NIH News Confirms Trend in Stem Cell 'Storage' Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
Date:3/26/2009

SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- David Koos, Chairman and CEO of San Diego-based Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) announced today that the important discovery reported on Wednesday, March 25 by researchers at the National Institutes of Health (NIH; www.nih.gov), which has implications for Leukemia treatment and artificially culturing blood cells, validates a new direction for stem cell "storage" facilities that meet rigid state and federal regulatory requirements. The researchers deciphered a key sequence of events governing whether the stem cells that produce red and white blood cells remain anchored to the bone marrow, or migrate into the circulatory system - an important discovery that will advance understanding of how blood cells and immune cells are generated.

"The findings of NIH researchers have implications for culturing infection-fighting immune cells outside the body, where they could be temporarily held in storage during chemotherapy and other treatments which suppress the immune system. This discovery confirms a new trend for commercial stem cell storage facilities for research and treatment of diseases, and their important role in public and private stem cell research efforts now and into the future," said Koos.

BMSN, an emerging research and development biotechnology company, opened its commercial cryogenic stem cell storage and processing facility in 2008 focusing on stem cells derived from cord blood and peripheral blood. BMSN's 15,000 sq. ft. cryogenic stem cell banking facility is highly secured and technologically advanced and is now fully operational.

"There are about 30 private cord blood storage facilities in the U.S. and more than 150 of these facilities located worldwide," stated Koos.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group In
'/>"/>

SOURCE Bio-Matrix Scientific Group Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
4. Barr Confirms Patent Challenge of Focalin(R) XR
5. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
6. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
7. Icahn Confirms Intention to Nominate Three Directors at Biogen
8. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
9. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Research Confirms Better Oil from New DuPont High Oleic Soybean Trait
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
(Date:11/21/2014)... , November 21, 2014 , ... comercial   Mariano Rodríguez es elegid vicepresidente ... KLOX está en marcha para comenzar de forma ... de heridas de reciente aprobación en Europa   , ... se complace al anunciar los siguientes nombramientos: ...
(Date:11/21/2014)... (PRWEB) November 19, 2014 The science ... lives was shared with more than 200 primary students ... students from the University of Otago Physics Department and ... The Otago students, members of the university’s OSA/SPIE Student ... in early September, giving children from small, rural schools ...
(Date:11/21/2014)... Los Angeles, CA (PRWEB) November 20, 2014 ... “A Short Walk to the Other Side” ... was an “Award-Winning Finalist in the “Fiction: Short Story” ... . , Jeffrey Keen, President and CEO of USA ... entries from mainstream and independent publishers, including Simon & ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... 2010 The Association for Career and Technical Education ... Role in Worker Retraining" that describes how career and ... adults and providing them the skills needed to re-enter the ... not only focus on local employment needs, but are also ...
... - YM BioSciences Inc. (NYSE Amex: YMI ... that identifies and advances a diverse portfolio of promising ... that it has priced an underwritten public offering of ... of $1.60 per share. The Company expects ...
... a biopharmaceutical company developing novel therapies to treat autoimmune ... announced that it has initiated a Phase 1 clinical ... profiles of TRX518, a monoclonal antibody designed to enhance ... effectively attack cancer cells.   The Phase ...
Cached Biology Technology:ACTE Releases Issue Brief Outlining Critical Role CTE Plays in Worker Retraining 2YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING 2YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING 3Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 2Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 3
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... 2014  The Secure Identity & Biometrics Association ... announce the formation of The Airport Entry and ... Identity and Biometric Entry and Exit Solutions Framework ... support from BORDERPOL, the international non-profit organization that ... expertise regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... reverse the symptoms of a rare form of muscular ... medical geneticists at Duke University Medical Center. Infants born ... die before they reach the age of two. The ... to muscles may have application in treating other muscular ...
... a new bacteria that is a natural cleanser for ... world, is an inexpensive and highly effective solution to ... be a master engineer,?said Ron Sims, biological and irrigation ... have put these carcinogens in our environment, and nature ...
... the flow of water molecules through the brain can help ... if a patient's tumor will shrink, a new study shows. ... developed the assessment, which they call a functional diffusion map. ... diffusion, or movement, of water through the brain and mapped ...
Cached Biology News:Muscle-targeted gene therapy reverses rare muscular dystrophy in mice 2Muscle-targeted gene therapy reverses rare muscular dystrophy in mice 3Solution to Pollution: New Bacteria Eats Toxic Waste 2Solution to Pollution: New Bacteria Eats Toxic Waste 3New imaging method gives early indication if brain cancer therapy is effective, U-M study shows 2New imaging method gives early indication if brain cancer therapy is effective, U-M study shows 3
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Mammals microRNA Microarray ...
... Optics LIBS2000+ Spectrometers (sold separately) in the ... Chamber to offer numerous configuration options and ... include a high-power 1064 nm Nd:YAG laser, ... sample positioning, laser spot diameter control from ...
...
... Varian 500-MS LC Ion Trap is ... LC/MS analysis where sensitivity, reliability and ... provides a robust platform for demanding ... resolution, and mass stability reflect the ...
Biology Products: